相关实验视频

Updated: May 21, 2025

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

Published on: May 12, 2022

开发中的非阿尔特美西宁抗疟药物:一篇综述

Dearie Glory Okwu¹, Rella Zoleko Manego², Stephan Duparc³

¹Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon; Department of Implementation Research, Bernhard Nocht Institute for Tropical Medicine & I. Dep. of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

|March 22, 2025

概括

新型非素抗疟药正在临床试验中取得进展,以对抗疟疾耐药性. 预计这些有前途的药物将提高治疗效率,并在未来十年内支持全球疟疾控制工作.

科学领域:

热带医学是一种热带医学.
传染病传染病传染病
药物开发药物开发

背景情况:

疟疾在2022年造成2.49亿例病例和6.08万例死亡,主要发生在非洲.
目前的治疗方法,如基于美素的组合疗法,面临着新兴的耐药性.
迫切需要新的抗疟疾药物来克服治疗挑战.

研究的目的:

审查最近抗疟疾药物的临床发展,重点关注非阿尔特米西宁化合物.
评估针对Profile-1.1的抗疟疾药物候选药物的进展情况.
提供对新兴疟疾治疗方法的概述.

主要方法:

数据来源于疟疾药物企业 (MMV) 和临床试验数据库 (2020-2024年).
审查了16项临床试验,包括安全性,耐受性和疗效研究.
评估的药物包括MMV533,ZY19489,INE963,GSK701/MMV367,KAE609,甘, lumefantrine-SDF,卡巴米昆,pyronaridine,和西帕加明等.

主要成果:

几种新型抗疟疾候选药物正在临床开发中取得进展.
在健康志愿者,实验感染者和疟疾患者中评估了安全性和有效性.
不同的药物组合和化合物正在针对无并发和严重的疟疾进行研究.

结论:

尽管有潜在的消耗,但具有新型作用机制的有前途的新型抗疟疾药正在推进.
这些药物预计将在十年内用于治疗疟疾.
新的抗疟疾药物可以加强治疗,降低耐药性,并帮助消除疟疾的努力.

关键词:

临床发展临床发展对疟疾的药物风险投资非艺术西宁的抗疟药物.严重的疟疾严重的疟疾目标候选人的个人资料.目标产品简介目标产品简介没有并发症的疟疾.

更多相关视频

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

相关概念视频

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...